<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677768</url>
  </required_header>
  <id_info>
    <org_study_id>BIO_ALS-01</org_study_id>
    <secondary_id>5RC1NS068179-02</secondary_id>
    <nct_id>NCT00677768</nct_id>
  </id_info>
  <brief_title>Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>BIO_ALS-01</acronym>
  <official_title>A Multicenter Study for the Validation of ALS Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Therapy Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples&#xD;
      from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron&#xD;
      diseases, as well as other neurodegenerative diseases and from people with no neurological&#xD;
      disorder. Through comparison of these samples, the researchers hope to learn more about the&#xD;
      underlying cause of ALS, as well as find unique biological markers, which could be used to&#xD;
      diagnose ALS and monitor disease progression.&#xD;
&#xD;
      Additionally, up to 600 blood samples will be collected for a sub-study for DNA analysis.&#xD;
      Studying components of the blood, such as DNA, may help us understand what happens when genes&#xD;
      function abnormally and how it might be related to disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Researchers tested what changes happen in volunteers with ALS that can be seen in the blood&#xD;
      and what changes are unique to ALS and are different from those found in healthy volunteers&#xD;
      and volunteers with neurological diseases other than ALS. These changes are called&#xD;
      biomarkers. Biomarkers for ALS have been found in blood collected in earlier phases of this&#xD;
      study. Biomarkers are non-genetic elements in your blood that may help to make diagnosing ALS&#xD;
      easier. In the next phase, comparison of these changes in the blood of volunteers with ALS&#xD;
      and without ALS will be used to confirm these biomarkers and to develop a tool to diagnose&#xD;
      and monitor progression of ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ALS Functional Rating Scale (ALSFRS-R)</measure>
    <time_frame>Every 6 months</time_frame>
    <description>The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">475</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Lou Gehrig's Disease</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Hereditary Spastic Paraparesis</condition>
  <arm_group>
    <arm_group_label>Early ALS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Suspected ALS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease Mimics of ALS</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Sample collection</description>
    <arm_group_label>Disease Mimics of ALS</arm_group_label>
    <arm_group_label>Early ALS</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Suspected ALS</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      650 blood samples (plasma and serum)will be collected from four groups: ALS volunteers&#xD;
      diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases,&#xD;
      volunteers with other neurological diseases and healthy control volunteers.&#xD;
&#xD;
      300 cerebrospinal fluid (CSF) samples will be collected from all four groups: ALS volunteers&#xD;
      diagnosed with ALS, volunteers with pure lower or pure upper motor neuron diseases,&#xD;
      volunteers with other neurological diseases and healthy control volunteers.&#xD;
&#xD;
      Up to 600 DNA samples will also be collected from all 4 groups: ALS volunteers diagnosed with&#xD;
      ALS, volunteers with pure lower or pure upper motor neuron diseases, volunteers with other&#xD;
      neurological diseases and healthy control volunteers.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Volunteers will be invited to participate in this study by their neurologists either in&#xD;
        clinic or at a regular scheduled appointment visit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. ALS Volunteers&#xD;
&#xD;
             Inclusion Criteria:&#xD;
&#xD;
               -  Diagnosis of possible (excluding volunteers with UMN signs ONLY), probable,&#xD;
                  probable-laboratory supported, or definite ALS, either sporadic or familial&#xD;
                  according to revised El Escorial criteria&#xD;
&#xD;
               -  Disease duration of less than or equal to two years from symptom onset&#xD;
&#xD;
               -  Age 30-80 years at the time of disease onset&#xD;
&#xD;
               -  Ability to provide informed consent&#xD;
&#xD;
               -  Ability to comply with study procedures&#xD;
&#xD;
               -  Medically safe to have lumbar puncture (lumbar puncture volunteers only)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Clinical evidence of chronic liver or renal failure&#xD;
&#xD;
               -  Presence of a bleeding disorder, problems with CSF pressure, allergy to local&#xD;
                  anesthetics, or a topical or other skin infection at the LP site (lumbar puncture&#xD;
                  volunteers only)&#xD;
&#xD;
               -  Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox,&#xD;
                  ticlid, warfarin or coumadin (lumbar puncture volunteers only)&#xD;
&#xD;
          2. Suspected ALS (PMND) Volunteers&#xD;
&#xD;
             Inclusion Criteria:&#xD;
&#xD;
               -  Diagnosis of suspected ALS defined as presence of UMN or LMN signs alone and the&#xD;
                  diagnosis of Clinically Probably Laboratory-Supported ALS CANNOT be proven by&#xD;
                  evidence in clinical grounds in conjunction with electrodiagnostic,&#xD;
                  neurophysiologic, neuroimaging or clinically laboratory studies&#xD;
&#xD;
               -  Disease duration of less than or equal to four years from symptom onset&#xD;
&#xD;
               -  Age 30-80 years at time of disease onset&#xD;
&#xD;
               -  Ability to provide informed consent&#xD;
&#xD;
               -  Ability to comply with study procedures&#xD;
&#xD;
               -  Medically safe to have lumbar puncture (lumbar puncture volunteers only)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Clinical evidence of chronic liver or renal failure&#xD;
&#xD;
               -  Genetically confirmed diagnosis of hereditary spastic paraparesis or spinal motor&#xD;
                  atrophy (SMA) disease&#xD;
&#xD;
               -  Presence of a bleeding disorder, problems with CSF pressure, allergy to local&#xD;
                  anesthetics, or a topical or other skin infection at the LP site (lumbar puncture&#xD;
                  volunteers only)&#xD;
&#xD;
               -  Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox,&#xD;
                  ticlid, warfarin or coumadin (lumbar puncture volunteers only)&#xD;
&#xD;
          3. Neurological Disease Mimic Volunteers&#xD;
&#xD;
             Inclusion Criteria:&#xD;
&#xD;
             Diagnosis of one of the following:&#xD;
&#xD;
             Pure Lower Motor Neuron Disease (LMND) mimics:&#xD;
&#xD;
               -  Multi-focal motor neuropathy&#xD;
&#xD;
               -  Autoimmune motor neuropathy&#xD;
&#xD;
               -  Cervical or lumbosacral radiculopathies&#xD;
&#xD;
             Peripheral mononeuropathies:&#xD;
&#xD;
               -  Ulnar neuropathy&#xD;
&#xD;
               -  Carpal tunnel syndrome/median neuropathy&#xD;
&#xD;
               -  Peroneal neuropathy&#xD;
&#xD;
               -  Sciatic neuropathy&#xD;
&#xD;
               -  Spinal muscular atrophy&#xD;
&#xD;
               -  Spinobulbar muscular atrophy (Kennedy's disease)&#xD;
&#xD;
               -  Charcot Marie-Tooth Disease (CMT)&#xD;
&#xD;
             Pure Upper Motor Neuron Disease (UMND) mimics:&#xD;
&#xD;
               -  Cervical myelopathy&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Hereditary spastic paraparesis&#xD;
&#xD;
               -  Age 30-80 years&#xD;
&#xD;
               -  Ability to provide informed consent&#xD;
&#xD;
               -  Ability to comply with study procedures&#xD;
&#xD;
               -  Medically safe to have lumbar puncture (lumbar puncture volunteers only)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Diagnosis of suspected, possible, probable or definite ALS either sporadic or&#xD;
                  familial&#xD;
&#xD;
               -  Presence of positive family history of ALS&#xD;
&#xD;
               -  Clinical evidence of chronic renal or liver failure&#xD;
&#xD;
               -  Presence of a bleeding disorder, problems with CSF pressure, allergy to local&#xD;
                  anesthetics, or a topical or other skin infection at the LP site (lumbar puncture&#xD;
                  volunteers only)&#xD;
&#xD;
               -  Use of any anti-platelet or anticoagulant drugs, such as plavix, aggrenox,&#xD;
                  ticlid, warfarin or coumadin (lumbar puncture volunteers only)&#xD;
&#xD;
          4. Healthy Control Volunteers Inclusion Criteria&#xD;
&#xD;
               -  Absence of a known neurological disorder.&#xD;
&#xD;
               -  Age 30 - 80 years.&#xD;
&#xD;
               -  Ability to provide informed consent.&#xD;
&#xD;
               -  Ability to comply with study procedures.&#xD;
&#xD;
               -  Medically safe to have lumbar puncture.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of ALS, myopathy, neuropathy, ALS mimic disorder or other neurodegenerative&#xD;
             disease.&#xD;
&#xD;
          -  Presence of positive family history of ALS.&#xD;
&#xD;
          -  Clinical evidence of chronic liver or renal failure.&#xD;
&#xD;
          -  Presence of bleeding disorder, problems with CSF pressure, allergy to local&#xD;
             anesthetics, or a topical or other skin infection at the LP site (LP research&#xD;
             volunteers only).&#xD;
&#xD;
          -  Research participant must not be taking anti-platelet or anticoagulant drugs, such as&#xD;
             plavix, aggrenox, ticlid, warfarin or coumadin (LP research volunteers only).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Berry, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Neurological Associates, Ltd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Neurology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Healthcare</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson/UMDNJ</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research, LLC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center, PACC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Health Care</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence ALS Clinic</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alsa.org</url>
    <description>ALS Association Website</description>
  </link>
  <link>
    <url>http://www.alsconsortium.org/</url>
    <description>NEALS ALS Consortium</description>
  </link>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>May 9, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2008</study_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>James D. Berry MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Plasma</keyword>
  <keyword>Cerebrospinal Fluid</keyword>
  <keyword>DNA</keyword>
  <keyword>Serum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Paraparesis</mesh_term>
    <mesh_term>Paraparesis, Spastic</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

